Recent Advances in Transition-Metal Catalyzed Oxidative Annulations to Benzazepines and Benzodiazepines

NOTICE: This is the peer reviewed version of the following article: Velasco-Rubio, A., Varela J. A., Saá C. (2020). Recent Advances in Transition-Metal Catalyzed Oxidative Annulations to Benzazepines and Benzodiazepines. Adv. Synth. Catal., 362, 22, 4861-4875. [doi: 10.1002/adsc.202000808]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archivingBenzazepines and benzodiazepines, benzofused seven-membered N-heterocycles, compose an important family of natural products and pharmaceuticals. Although certainly important and effectives, classical synthetic methods of these cyclic compounds involve methodologies that often require multistep procedures, with generation of waste materials and lack of sustainability. By contrast, cycloadditions based on transition metal catalyzed C-H bond activations (oxidative annulations) have emerged as appealing strategies for more sustainable synthetic processes. In this review, we focus our attention to describe the state-of-the-art transition-metal catalyzed annulations via C-H activations to benzazepines and benzodiazepines.This work has received financial support from MINECO (project CTQ2017-87939R and ORFEO-CINQA network RED2018- 102387-T), the Xunta de Galicia (project ED431C 2018/04 and Centro singular de investigación de Galicia accreditation 2019- 2022, ED431G 2019/03) and the European Union (European Regional Development Fund – ERDF)S

New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

In anxiety, depression and psychosis, there has been frustratingly slow progress in developing novel therapies that make a substantial difference in practice, as well as in predicting which treatments will work for whom and in what contexts. To intervene early in the process and deliver optimal care to patients, we need to understand the underlying mechanisms of mental health conditions, develop safe and effective interventions that target these mechanisms, and improve our capabilities in timely diagnosis and reliable prediction of symptom trajectories. Better synthesis of existing evidence is one way to reduce waste and improve efficiency in research towards these ends. Living systematic reviews produce rigorous, up-to-date and informative evidence summaries that are particularly important where research is emerging rapidly, current evidence is uncertain and new findings might change policy or practice. Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) aims to tackle the challenges of mental health science research by cataloguing and evaluating the full spectrum of relevant scientific research including both human and preclinical studies. GALENOS will also allow the mental health community-including patients, carers, clinicians, researchers and funders-to better identify the research questions that most urgently need to be answered. By creating open-access datasets and outputs in a state-of-the-art online resource, GALENOS will help identify promising signals early in the research process. This will accelerate translation from discovery science into effective new interventions for anxiety, depression and psychosis, ready to be translated in clinical practice across the world

New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

In anxiety, depression and psychosis, there has been frustratingly slow progress in developing novel therapies that make a substantial difference in practice, as well as in predicting which treatments will work for whom and in what contexts. To intervene early in the process and deliver optimal care to patients, we need to understand the underlying mechanisms of mental health conditions, develop safe and effective interventions that target these mechanisms, and improve our capabilities in timely diagnosis and reliable prediction of symptom trajectories. Better synthesis of existing evidence is one way to reduce waste and improve efficiency in research towards these ends. Living systematic reviews produce rigorous, up-to-date and informative evidence summaries that are particularly important where research is emerging rapidly, current evidence is uncertain and new findings might change policy or practice. Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) aims to tackle the challenges of mental health science research by cataloguing and evaluating the full spectrum of relevant scientific research including both human and preclinical studies. GALENOS will also allow the mental health community-including patients, carers, clinicians, researchers and funders-to better identify the research questions that most urgently need to be answered. By creating open-access datasets and outputs in a state-of-the-art online resource, GALENOS will help identify promising signals early in the research process. This will accelerate translation from discovery science into effective new interventions for anxiety, depression and psychosis, ready to be translated in clinical practice across the world

Maternal urinary cell free fetal DNA in relation to gestational age

Objectives: To evaluate the presence of cell-free fetal DNA in the maternal urine in relation to gestational age as a potential source for non-invasive prenatal diagnosis. Material and methods: One hundred and sixty normal pregnant women were included in the study; 80 women pregnant with male fetuses and 80 women pregnant with female fetuses. Maternal urine of all patients was examined at 12, 16 and 20 wks’ gestation for the SRY gene (sex-determining region Y) as a cffDNA (cell free fetal DNA) marker and Ribonuclease P RNA component H1 (RPPH1) as a total cfDNA (cell free DNA) marker using a quantitative real-time PCR assay. Results: SRY gene was detected in maternal urine of those pregnant with male fetuses starting from 16 weeks in 25% (20/80) of cases only and in 80% of cases (64/80) at 20 weeks, but it was not detected at 12 weeks. All women female fetuses were negative for SRY gene. Conclusions: Cell free fetal DNA in maternal urine was not detected in early gestational age using SRY gene alone despite the use of extraction kit specific for extraction of Free-circulating nucleic acids and highly sensitive reported PCR technique. Further studies should be done to evaluate whether cell free fetal DNA in maternal urine can be detected after reaching a certain threshold in blood